TG reports updated Phase IIa MS data for anti-CD20 mAb

TG Therapeutics Inc. (NASDAQ:TGTX) reported updated data from a Phase IIa trial evaluating ublituximab (TG-1101, TGTX-1101) to treat relapsing multiple sclerosis. Ublituximab is a glycoengineered mAb against CD20.

Among 38 evaluable patients with relapsing MS, ublituximab reduced the mean number of T1 gadolinium-enhancing

Read the full 420 word article

User Sign In